On the other hand, data observed in melanoma patients treated with anti-CTLA-4 or anti-PD-1 therapy showed that the increase of sPD-L1 with a FC > 1.5, after 5 months of treatment, was associated with a favorable clinical outcome [19]. Here, SPDL1 is linked to melanoma.